Skip to main content

MS treatment gains favor relapsing over progressive forms

By MS Buddy ·

Summarized from The New England journal of medicine, Jul 2026 · PubMed · DOI. AI-generated summary. Not medical advice.

Review · people with relapsing and progressive forms of MS

Research by Stephen Hauser at the University of California, San Francisco.

How do treatment options differ for relapsing and progressive MS?

Key Takeaway

Treatments have improved outcomes for relapsing MS, but options for progressive MS remain limited.

Two winding cut-paper paths, one with many stepping stones and the other with only a few.
Credibility
Interest
Share:1 min read

What They Found

This review describes how MS damages myelin (the protective covering around nerves). Nerve damage also plays a major role in long-term disability. Treatments that change immune activity have improved outcomes for people with relapsing MS. Treatment options for progressive MS remain limited. The review also stresses the importance of symptom care and lifestyle support.

Who Should Care and Why

This review is about people with MS, not a new group of study participants. It discusses treatment gains for people with relapsing forms of MS. It also describes the limited options for people with progressive forms. People with MS symptoms may find its discussion of symptom care relevant. The review links symptom care and lifestyle support to quality of life and disability.

Important Considerations

This is a review, not a report of a new treatment test. It does not give a sample size or compare specific treatments. It does not show that a new treatment prevents worsening or repairs myelin.

AI-generated summary — for informational purposes only, not medical advice

Read the original abstract

Published in The New England journal of medicine by . Reproduced from the PubMed record.

Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, causing episodes of neurologic dysfunction and often gradual disease progression. The immune system primarily targets myelin, the protective covering of nerve fibers, leading to inflammation and damage, and secondary neurodegeneration is a major cause of long-term disability. Common symptoms include vision problems, sensory disturbances, muscle weakness, balance difficulties, and bladder dysfunction. Important advances in treatment have improved outcomes in patients with relapsing forms of multiple sclerosis, particularly through highly effective immune-modifying therapies such as CD20-targeting monoclonal antibodies. However, treatment options for progressive forms remain limited, which highlights the need for therapies that can prevent progression and promote myelin repair. Comprehensive symptom management and lifestyle support are also essential to maintaining quality of life and reducing disability.

The app

Check out the MS Buddy app

It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play

Related MS research

Rounded stem cells with visible nuclei float against a muted blue-gray background.
MS stem cell transplants mostly done without admission

11/19/2026

A review of one MS stem cell transplant program found most procedures avoided hospital admission. Be

Read More
Paper bands support a bowl of blue droplets; a few drops sit outside, and a dotted path leads to a guiding hand.
Remotely guided muscle training eased urine leaks in MS

11/20/2026

A review of three trials found remotely guided muscle exercises eased urine leaks and bladder overac

Read More
Paper nerve branches sit within a curved protective layer, with most small paper shapes outside and a few nearby.
Stem cell transplants curb disease activity in active MS

11/19/2026

A review finds lasting control of disease activity after stem cell transplants in selected people wi

Read More
Two curving ribbons, one with fewer loose knots; the knots on both ribbons are the same size and length.
MS drugs cut relapses but did not change relapse recovery

11/19/2026

Across four trials in relapsing-remitting MS, long-term treatments reduced relapses but did not chan

Read More
Muted blue and clay ribbons curve across an off-white background, wrapped in soft layers of varying thickness.
Planned MS study will test scans to track worsening

11/16/2026

A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS

Read More
Brain outline filled with fine, branching nerve fibers on an off-white background.
In relapsing MS, Mavenclad users' thinking scores rose

11/14/2026

In a review of records for 173 people taking Mavenclad for MS, most had no relapses over two years.

Read More

Not all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.